CClinicalTrials.gg
CompletedNCT05635539Updated Apr 29, 2024

Weight Loss in Patients With COVID-19 and Influenza in Comorbidity With NCDs: a Pilot Prospective Clinical Trial

An interventional study of "Analimentary detoxication" (ANADETO) weight loss based on very-low-calorie-diet in Clinical Trial, sponsored by University Medical Center, Kazakhstan. Completed at 1 site in Kazakhstan. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by University Medical Center, Kazakhstan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
25 Years to 80 Years
Sex
All
01

Study summary

The goal of this study was to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs.

Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan.

Read the detailed description

Study Design. A 6-week, open, pilot prospective clinical trial with the intention-to-treat principle.

Participants: The study enrolled 72 adult people (38 women) aged from 25 to 80 years with moderate-to-severe cases COVID and Influenza in comorbidity with NCDs as T2D, hypertension, and NASH. All patients with the ARDs had in comorbidity with one or more NCDs. All patients refused for pharmacology therapy due to: either previous unsuccessful drug results; or an antimicrobial resistance profile; or drug allergy; or reluctance to take medication; or iatrogenic fear (iatrophobia); or a rich failed experience in drug treatment; and NASH.

All the patients were admitted into the out-patient department in 3-5 days after illness onset. The study was carried out in the Republic of Kazakhstan from November, 2020, through July, 2022 at University Medical Center (Astana) and ANADETO medical center.

02

Conditions studied

  • Clinical Trial

Browse trials for

Keywords

  • COVID-19
  • Influenza
  • Non-Communicable Diseases (NCDs)
  • fast weight loss
03

Who can participate

Ages eligible
25 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • written informed consent form;
  • patients with fever
  • patients refused for pharmacology therapy
  • weight loss treatment for 12-14 days and +4 weeks follow-up (total 6 weeks)

Exclusion criteria

Exclusion Criteria:

  • patients with acute respiratory failure and assisted ventilation requirement
  • respiratory rate ≥ 30 times per minute
  • oxygen saturation ≤ 93% by finger oximetry at resting status
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    patients with COVID

    27 patients with COVID in comorbidity with NCDs as T2D, hypertension, and NASH

    Dietary Supplement: "Analimentary detoxication" (ANADETO) weight loss based on very-low-calorie-diet

  • Experimental
    patients with Influenza

    35 patients with Influenza in comorbidity with NCDs as T2D, hypertension, and NASH

    Dietary Supplement: "Analimentary detoxication" (ANADETO) weight loss based on very-low-calorie-diet

Interventions

  • Dietary supplement"Analimentary detoxication" (ANADETO) weight loss based on very-low-calorie-diet

    calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.

    Also known as: very-low-calorie-diet

05

What researchers measure

Primary outcomes

  1. Clinic and infectious tests for COVID and Influenza

    COVID was diagnosed primarily by direct detection of SARS-CoV-2 RNA by nucleic acid amplification tests with a real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay. To diagnosis of the flu was used a RT-PCR test called the Flu SC2 Multiplex Assay.

    Time frame: Change from Baseline at 6 Weeks

  2. weight loss during 14 days

    kg

    Time frame: Change from Baseline at 14 days

  3. C-reactive protein

    mg/L

    Time frame: Change from Baseline at 6 Weeks

Secondary outcomes

  1. fasting blood glucose

    mmol/L

    Time frame: Change from Baseline at 6 Weeks

  2. glycosylated hemoglobin A1c

    percent

    Time frame: Change from Baseline at 6 Weeks

  3. blood insulin

    nU/L

    Time frame: Change from Baseline at 6 Weeks

  4. systolic/diastolic blood pressures

    mmHg

    Time frame: Change from Baseline at 6 Weeks

  5. blood lipids

    mmol/L

    Time frame: Change from Baseline at 6 Weeks

  6. alanine aminotransferase and aspartate aminotransferase

    U/L

    Time frame: Change from Baseline at 6 Weeks

  7. chest computed tomography scan

    image

    Time frame: Change from Baseline at 14 days

06

Study locations

1 site
  • Kuat Pernekulovich Oshakbayev
    Astana, 010000, Kazakhstan
07

References and documents

Individual participant data

Plan to share: No — The investigators will make data available to any investigator/reviewer on their own request, so that the personal privacy of our patients cannot be compromised.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05635539
Lead sponsor
University Medical Center, Kazakhstan
Responsible party
Kuat Oshakbayev (a principal investigator, University Medical Center, Kazakhstan) — Principal investigator
First posted
Dec 2, 2022
Start date
Aug 1, 2020
Primary completion
Apr 30, 2022
Completion
Jul 31, 2022
Last update
Apr 29, 2024

Study contacts

Alaty N Nabiyev, Dr.
study director · University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion